MedTrace Logo

Aripiprazole for the Treatment of Refractory Anxiety

NCT00438386 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2009-08-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether aripiprazole is effective in the treatment of refractory panic and generalized anxiety disorder.

Conditions

  • Generalized Anxiety Disorder
  • Panic Disorder

Interventions

DRUG

Aripiprazole

Sponsors & Collaborators

Principal Investigators

  • Mark H Pollack, M.D. · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00438386 on ClinicalTrials.gov